Company intelligence / Profile preview

Aidence

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

Aidence develops CE-certified AI-powered software solutions for automated detection, quantification, and reporting of lung nodules on chest CT scans. Their flagship product suite "Veye" supports early lung cancer diagnosis and standardized reporting. The technology has been validated through clinical use across the UK NHS and major European centers. The company has received grants, awards, and partnerships with leading institutions such as AstraZeneca and Google Health to expand its impact in lung cancer screening pathways. In January 2022 it was acquired by RadNet.

Therapeutic areas: OncologyPulmonology
Modalities: DeviceNon-pharmacological therapy
Industry: Medical Imaging

Partnerships

AstraZenecaGoogle HealthErasmus MCThe Netherlands Cancer InstituteNHS England’s Targeted Lung Health Checks programInceptoThirona

Beyond the preview

Go deeper on Aidence.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aidence.

Explore the full profile